Microneedling for Acne Scars: What a 2026 Split-Face Trial Found
If you have ever stood in front of a mirror tracing the dips and shadows left behind by years of breakouts, you already know that acne scars are more than a cosmetic inconvenience — they affect confidence, daily life, and how we see ourselves. In 2026, a tightly controlled clinical trial put two of the most talked-about scar treatments head-to-head on the same face, measuring progress with one of dermatology's gold-standard scoring tools. The numbers are illuminating, and the implications go well beyond the clinic.
What exactly is the ECCA score, and why does it matter for measuring scar improvement?
The ECCA score — short for Échelle d'Évaluation Clinique des Cicatrices d'Acné, a validated French clinical grading scale — is the dermatology field's primary tool for objectively quantifying atrophic acne scar severity, assigning weighted values to scar type and count so that different clinicians can compare results reliably. Because it is validated and reproducible, peer-reviewed trials rely on it as a primary endpoint rather than subjective "before and after" photographs alone. The primary endpoint of the landmark 2026 split-face trial was precisely the change in ECCA score , making its data especially trustworthy for people evaluating real-world scar treatment options.
What did the 2026 split-face trial actually do, and who was studied?
Researchers conducted an exploratory split-face study comparing radiofrequency microneedling (RFMN) and fractional carbon dioxide laser (FCO2) in patients with facial atrophic acne scars. The split-face design is considered especially rigorous because each participant acts as their own control — one half of the face receives one treatment, the other half receives the other — eliminating the genetic and lifestyle variables that can confound separate-group comparisons.
In this prospective, randomized, evaluator-blinded exploratory trial, 33 patients were enrolled and 30 completed the study; each facial side was assigned to RFMN or FCO2, and three treatment sessions were performed at 8-week intervals. Secondary outcomes were comprehensive: they included physician-rated improvement, satisfaction, Dermatology Life Quality Index, pain, recovery-related outcomes, and adverse events.
What were the headline ECCA score results — did microneedling actually work?
Both treatments produced clinically meaningful reductions in scar severity. Mean ECCA scores decreased from 54.73 to 30.53 with RFMN and from 53.67 to 31.03 with FCO2, without a significant between-treatment difference. In plain terms, radiofrequency microneedling trimmed the scar score by roughly 44% and the fractional laser trimmed it by roughly 42% — essentially identical efficacy from a statistical standpoint. However, radiofrequency microneedling was associated with faster recovery, fewer pigment-related adverse events, and higher patient satisfaction regarding safety.
This equivalence in efficacy — paired with a meaningfully better tolerability profile for microneedling — is the trial's most clinically important finding.
Why does radiofrequency microneedling produce results comparable to a laser without the same downtime?
Understanding the mechanism helps clarify why this is biologically plausible. Radiofrequency microneedling (RFMN) combines two wound-healing stimuli in a single pass: the mechanical microchannels created by the needles and the thermal energy delivered by radiofrequency current at a precise depth. Both signals trigger the skin's repair cascade — collagen synthesis, fibroblast proliferation, and extracellular matrix remodeling — without broadly ablating the surface. Fractional CO₂ laser, by contrast, vaporises microscopic columns of tissue, which is highly effective but also creates a more extensive surface wound.
RFMN was associated with shorter erythema, pain, swelling, and scab-detachment durations and fewer post-inflammatory hyperpigmentation events. For patients with Fitzpatrick skin types III–V — who are most susceptible to post-inflammatory hyperpigmentation (PIH) — this tolerability advantage is not trivial; it is often the deciding factor in treatment selection.
What does a separate 2025 split-face trial add to this picture?
The 2026 findings complement an earlier 2025 randomised controlled trial published in the Journal of Cosmetic Dermatology, which explored whether combining topical insulin with microneedle fractional radiofrequency could further accelerate improvement. That split-face, double-blinded, placebo-controlled trial involved 30 participants with atrophic acne scars; each side of the face was randomly treated with a combination of microneedle fractional radiofrequency and topical insulin, or a placebo, every four weeks for four consecutive sessions. The ECCA reductions were dramatic on both sides: the topical insulin sides exhibited a reduction of 46.77% ± 21.33% in ECCA score (p ≤ 0.001), while the placebo sides showed a reduction of 46.39% ± 20.14% in ECCA (p ≤ 0.001). The consistency of ~46% ECCA reduction across both arms again underscores just how potent microneedling-based energy delivery is as a standalone mechanism.
Where does at-home microneedling fit into this clinical context?
Professional radiofrequency microneedling devices operate at energy levels and needle depths that are not replicated in consumer tools — and it is important to be transparent about that boundary. However, the biological mechanism of collagen induction through micro-injury is the same principle at work across the spectrum of needle-based devices, and consistent, low-depth at-home use can meaningfully support skin texture and tone between professional sessions or as an accessible starting point for those earlier in their scar-treatment journey.
If you are exploring where to begin, the SKINDELÚX Microneedling Pen is designed for controlled, at-home collagen induction — a complement to professional care, not a replacement for it. Always begin with shorter needle depths and introduce the device gradually; consult a dermatologist before starting if you have active acne, significant scarring, or darker skin tones.
What does a 2026 network meta-analysis say about microneedling's overall ranking?
A sweeping 2026 systematic review and network meta-analysis published in PMC synthesised data from 68 randomised controlled trials covering 4,480 patients. A total of 68 randomised controlled trials were enrolled comprising 4,480 patients; laser + platelet-rich plasma ranked best in reducing ECCA scores (SUCRA: 98.4%), while microneedling was ranked as the most tolerable in terms of pain (SUCRA: 72.6%). In other words, across the entire landscape of acne scar interventions, microneedling occupies a unique position: it may not outrank every laser combination on raw efficacy, but it leads on the tolerability metric that makes consistent long-term treatment adherence realistic for most people.
What are the practical takeaways for someone considering scar treatment in 2026?
The convergence of evidence from multiple rigorous split-face trials points to several actionable conclusions. First, both radiofrequency microneedling and fractional CO₂ laser produce meaningful, statistically significant reductions in validated ECCA scar scores — so both are legitimate options. Second, the choice between them should be driven by recovery tolerance, skin phototype, and access rather than by expected efficacy. Third, radiofrequency microneedling may provide a more favorable balance of efficacy and tolerability for the treatment of atrophic acne scars — a conclusion directly stated by the 2026 trial authors. Fourth, patience and consistency matter: all trials required multiple sessions spaced weeks apart before peak results were observed.
Skin science in 2026 confirms what many practitioners have intuitively known — microneedling belongs at the centre of any evidence-based acne scar protocol.
Ready to support your skin's collagen journey at home? The SKINDELÚX Microneedling Pen brings precision needle-depth control to your routine — designed to complement, not replace, professional dermatological care. Use it responsibly, consistently, and always with clean technique.
Frequently Asked Questions
- What is the ECCA score used for in acne scar research?
- The ECCA (Échelle d'Évaluation Clinique des Cicatrices d'Acné) is a validated, dermatologist-used clinical grading scale that assigns weighted numerical scores to atrophic acne scars based on scar type and count. It is widely used as a primary endpoint in clinical trials because it allows objective, reproducible comparison of scar severity before and after treatment, across different clinicians and study sites.
- What is a split-face trial and why is it considered more reliable?
- A split-face trial assigns different treatments to each half of the same patient's face. Because both sides share identical genetics, sun history, skin type, and systemic factors, variability between participants is eliminated. This design makes it easier to isolate the true difference (or equivalence) between two treatments, and it is considered one of the most rigorous methods for comparing topical or device-based cosmetic interventions.
- How many sessions of radiofrequency microneedling are typically needed for acne scars?
- The 2026 split-face trial delivered three treatment sessions at 8-week intervals, which is consistent with standard clinical protocols. Most dermatologists recommend between 3 and 6 sessions depending on scar depth and type, with the most significant improvements typically emerging after the second or third session as new collagen continues to mature over several months.
- Is radiofrequency microneedling safe for darker skin tones?
- The evidence suggests RF microneedling has a favourable pigmentary safety profile compared to ablative lasers. The 2026 trial found fewer post-inflammatory hyperpigmentation (PIH) events with RFMN than with fractional CO₂ laser. Because RF energy is delivered beneath the epidermis (the pigment-containing layer), there is less surface disruption — a meaningful advantage for Fitzpatrick skin types III through VI. However, individual assessment by a board-certified dermatologist is always recommended before treatment.
- Can at-home microneedling devices help with acne scars?
- At-home microneedling devices operate at much shallower needle depths and lower energy levels than professional RF microneedling, so they cannot replicate clinical trial results. However, consistent use of at-home devices can stimulate mild collagen induction and improve skin texture over time, and they serve as a useful complement between professional appointments. They are not a replacement for in-clinic treatment of moderate-to-severe atrophic scarring.
- What scar types respond best to microneedling?
- Rolling scars — which have gently sloping edges and are caused by fibrous tethering beneath the skin — tend to respond most readily to microneedling because the mechanical disruption of sub-dermal bands allows the skin to re-elevate. Boxcar scars (sharply defined depressions) show moderate response, while ice-pick scars (deep, narrow channels) are generally the least responsive to needle-based therapies alone and may benefit from combination approaches such as punch excision or TCA CROSS prior to resurfacing.
Sources:
1. Li W, et al. Comparative efficacy, recovery, and pigmentary safety of radiofrequency microneedling and fractional carbon dioxide laser for facial atrophic acne scars: a prospective randomized split-face trial. Journal of Dermatological Treatment. 2026. https://pubmed.ncbi.nlm.nih.gov/42312398/ | Full text (Taylor & Francis)
2. Rattananukrom T, et al. Efficacy of Microneedle Fractional Radiofrequency Combined With Topical Insulin for the Treatment of Facial Atrophic Acne Scars: A Split-Face, Double-Blinded, Randomized, Placebo-Controlled Trial. Journal of Cosmetic Dermatology. 2025. https://onlinelibrary.wiley.com/doi/10.1111/jocd.70033
3. Comparison of Non-insulated Microneedle Fractional Radiofrequency and Ablative Fractional Carbon Dioxide Laser for the Treatment of Facial Atrophic Acne Scarring: A Pilot Randomized Split-face Clinical Study. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12228042/
4. Optimal treatment options for acne scars in patients with historic acne: a systematic review and network meta-analysis. PMC. 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12515001/